MRK Merck & Co., Inc.
Healthcare$119.76-2.16%ClosedMarket Cap: $295.79B
As of 2026-05-26
Valuation
P/E (TTM)
16.17
PEG
2.43
P/B
6.60
P/S
4.61
EV/EBITDA
15.25
DCF Value
$218.64
FCF Yield
4.7%
Div Yield
2.7%
Margins & Returns
Gross Margin
75.9%
Operating Margin
27.6%
Net Margin
13.6%
ROE
17.9%
ROA
6.9%
ROIC
13.3%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $16.29B | 81.9% | $-1.88B | $-4.24B | $— | $0.85 |
| Q4 null | $16.32B | 70.5% | $6.16B | $2.96B | $— | $0.85 |
| FY null | $64.93B | 72.0% | $23.49B | $18.25B | $— | $3.28 |
| Q3 null | $17.18B | 75.6% | $7.46B | $5.79B | $— | $0.81 |
| Q2 null | $15.80B | 75.7% | $6.36B | $4.43B | $— | $0.81 |
| Q1 null | $15.62B | 75.1% | $6.71B | $5.08B | $— | $0.81 |
| Q4 null | $15.62B | 75.5% | $4.35B | $3.74B | $— | $0.81 |
| FY null | $64.17B | 76.3% | $20.22B | $17.12B | $— | $3.12 |
| Q3 null | $16.66B | 75.5% | $3.98B | $3.16B | $— | $0.77 |
| Q2 null | $16.11B | 76.8% | $6.13B | $5.46B | $— | $0.77 |
| Q1 null | $15.78B | 77.6% | $5.76B | $4.76B | $— | $0.77 |
| Q4 2023 | $14.63B | 73.3% | $-1.71B | $-1.23B | $-0.48 | $0.77 |